Financials data is unavailable for this security.
View more
Year on year Gufic Biosciences Ltd grew revenues 16.80% from 6.91bn to 8.07bn while net income improved 8.07% from 797.05m to 861.36m.
| Gross margin | 52.39% |
|---|---|
| Net profit margin | 10.60% |
| Operating margin | 15.81% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Gufic Biosciences Ltd fell by 274.65m. Cash Flow from Financing totalled 823.81m or 10.21% of revenues. In addition the company used 74.57m for operations while cash used for investing totalled 1.02bn.
| Cash flow per share | 10.41 |
|---|---|
| Price/Cash flow per share | 38.82 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 6.34%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 0.06% |
|---|---|
| Div growth rate (5 year) | 14.87% |
| Payout ratio (TTM) | 1.16% |
| EPS growth(5 years) | 25.40 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 6.18 |
More ▼
